Key facts
- Biobeat’s last known valuation is $102.7M (May 2024).
- It has raised $71.8M; the latest was Later Stage VC ($50.0M) in Dec 2025.
- Notable investors include OrbiMed, Ally Bridge Group, and Ventures, Elevage Medical Technologies, ARC Innovation Center — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Biobeat
- ·The full record, as it builds
Funding rounds
No funding rounds for Biobeat are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biobeat
Developer of a wearable remote patient monitoring device designed to measure vital signs using wireless, non-invasive, and medical-grade technology. The company's device specialises in monitoring vital signs and other medically relevant parameters, including consciousness, saturation, pulse, temperature, and perspiration, enabling patients to have control over their everyday life, health, and sickness.
- Sector
- Healthcare
- HQ
- Petah Tikva, Israel
- Founded
- 2014
- Employees
- 71
- Website
- bio-beat.com/
- Ownership
- Privately Held (backing)
Biobeat doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biobeat shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biobeat in its N-PORT filings yet. We sweep new filings monthly.